Frontlight ResearchEarly access
WithdrawnNo phase
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Key facts
- Who runs it
- Pfizer
- Trial code
- Status
- Withdrawn
- Started
- 16 May 2025
- Ended
- 16 Aug 2025
- Type of study
- Observational
- Treatments tested
- Zirabev
- Record updated
- 19 March 2025
- Why it stopped
- The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Other criteria
- Inclusion criteria; Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Adults over 19 years old
- Patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme
- Patients eligible for Zirabev dosage based on local product document, local treatment guidelines and clinical judgment of the medical team
- Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study; Exclusion criteria; Patients meeting any of the following criteria will not be included in the study:
- Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information
- Patients for whom Zirabev is contraindicated according to the local product document
About the trial
What the trial wants to find out
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.
The group in the trial
- Participants receiving Zirabev
Treatment: Zirabev
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
- Record updated
- 19 March 2025